China's medical products administrator approved clinical trials for a herpes zoster vaccine developed by Chongqing Zhifei Biological Products (SHE:300122) subsidiary Anhui Zhifei Longcom Biopharmaceutical.
The subsidiary may begin clinical trials for the mRNA vaccine for the condition, also known as shingles, if regulators do not receive negative opinions regarding the drug, the filing said.
Shingles is a viral condition that causes a painful rash and nerve damage.
Longcom also received clinical trial approval for its freeze-dried varicella-zoster vaccine for chickenpox, a separate filing said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments